THU0088 Structural damage progression in patients treated with methotrexate, baricitinib monotherapy or baricitinib + methotrexate based on their level of clinical response in the phase 3 ra-begin study

D Van Der Heijde; P Durez; G Schett; E Naredo; M Østergaard; G Meszaros; N Bello; I De La Torre; P Lopez-Romero; D Schlichting; E Nantz; R Fleischmann

doi:10.1136/annrheumdis-2017-eular.2223

THU0088 Structural damage progression in patients treated with methotrexate, baricitinib monotherapy or baricitinib + methotrexate based on their level of clinical response in the phase 3 ra-begin study

D Van Der Heijde, P Durez, G Schett, E Naredo, M Østergaard, G Meszaros, N Bello, I De La Torre, P Lopez-Romero, D Schlichting, E Nantz, R Fleischmann

Department of Clinical Medicine

Original language	English
Journal	Annals of the Rheumatic Diseases
Volume	76
Issue number	Suppl 2
Pages (from-to)	233
ISSN	0003-4967
DOIs	https://doi.org/10.1136/annrheumdis-2017-eular.2223
Publication status	Published - 2017

Access to Document

10.1136/annrheumdis-2017-eular.2223

233.1.full.pdfFinal published version, 125 KB

Cite this

Heijde, D. V. D., Durez, P., Schett, G., Naredo, E., Østergaard, M., Meszaros, G., Bello, N., Torre, I. D. L., Lopez-Romero, P., Schlichting, D., Nantz, E., & Fleischmann, R. (2017). THU0088 Structural damage progression in patients treated with methotrexate, baricitinib monotherapy or baricitinib + methotrexate based on their level of clinical response in the phase 3 ra-begin study. Annals of the Rheumatic Diseases, 76(Suppl 2), 233. https://doi.org/10.1136/annrheumdis-2017-eular.2223

THU0088 Structural damage progression in patients treated with methotrexate, baricitinib monotherapy or baricitinib + methotrexate based on their level of clinical response in the phase 3 ra-begin study. / Heijde, D Van Der; Durez, P; Schett, G et al.

In: Annals of the Rheumatic Diseases, Vol. 76, No. Suppl 2, 2017, p. 233.

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

Heijde, DVD, Durez, P, Schett, G, Naredo, E, Østergaard, M, Meszaros, G, Bello, N, Torre, IDL, Lopez-Romero, P, Schlichting, D, Nantz, E & Fleischmann, R 2017, 'THU0088 Structural damage progression in patients treated with methotrexate, baricitinib monotherapy or baricitinib + methotrexate based on their level of clinical response in the phase 3 ra-begin study', Annals of the Rheumatic Diseases, vol. 76, no. Suppl 2, pp. 233. https://doi.org/10.1136/annrheumdis-2017-eular.2223

Heijde DVD, Durez P, Schett G, Naredo E, Østergaard M, Meszaros G et al. THU0088 Structural damage progression in patients treated with methotrexate, baricitinib monotherapy or baricitinib + methotrexate based on their level of clinical response in the phase 3 ra-begin study. Annals of the Rheumatic Diseases. 2017;76(Suppl 2):233. doi: 10.1136/annrheumdis-2017-eular.2223

@article{e48d87a67fd14b478068eb3e1da6ebea,

title = "THU0088 Structural damage progression in patients treated with methotrexate, baricitinib monotherapy or baricitinib + methotrexate based on their level of clinical response in the phase 3 ra-begin study",

author = "Heijde, {D Van Der} and P Durez and G Schett and E Naredo and M {\O}stergaard and G Meszaros and N Bello and Torre, {I De La} and P Lopez-Romero and D Schlichting and E Nantz and R Fleischmann",

year = "2017",

doi = "10.1136/annrheumdis-2017-eular.2223",

language = "English",

volume = "76",

pages = "233",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "B M J Group",

number = "Suppl 2",

}

TY - ABST

T1 - THU0088 Structural damage progression in patients treated with methotrexate, baricitinib monotherapy or baricitinib + methotrexate based on their level of clinical response in the phase 3 ra-begin study

AU - Heijde, D Van Der

AU - Durez, P

AU - Schett, G

AU - Naredo, E

AU - Østergaard, M

AU - Meszaros, G

AU - Bello, N

AU - Torre, I De La

AU - Lopez-Romero, P

AU - Schlichting, D

AU - Nantz, E

AU - Fleischmann, R

PY - 2017

Y1 - 2017

U2 - 10.1136/annrheumdis-2017-eular.2223

DO - 10.1136/annrheumdis-2017-eular.2223

M3 - Conference abstract in journal

SN - 0003-4967

VL - 76

SP - 233

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

IS - Suppl 2

ER -